CN111840562A - Application of USP7 inhibitor in ABC-DLBCL treatment drug - Google Patents
Application of USP7 inhibitor in ABC-DLBCL treatment drug Download PDFInfo
- Publication number
- CN111840562A CN111840562A CN202010859627.8A CN202010859627A CN111840562A CN 111840562 A CN111840562 A CN 111840562A CN 202010859627 A CN202010859627 A CN 202010859627A CN 111840562 A CN111840562 A CN 111840562A
- Authority
- CN
- China
- Prior art keywords
- usp7
- dlbcl
- abc
- cells
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 title claims abstract description 103
- 102000052151 Ubiquitin-Specific Peptidase 7 Human genes 0.000 title claims abstract description 97
- 108700011958 Ubiquitin-Specific Peptidase 7 Proteins 0.000 title claims abstract description 97
- 101150020913 USP7 gene Proteins 0.000 title claims abstract description 92
- 229940126752 Ubiquitin-specific protease 7 inhibitor Drugs 0.000 title claims abstract description 91
- 239000003112 inhibitor Substances 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims description 10
- 230000014509 gene expression Effects 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108010087230 Sincalide Proteins 0.000 claims abstract description 11
- 230000006907 apoptotic process Effects 0.000 claims abstract description 11
- 238000010609 cell counting kit-8 assay Methods 0.000 claims abstract description 11
- 238000011161 development Methods 0.000 claims abstract description 11
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims abstract description 11
- 150000003384 small molecules Chemical class 0.000 claims abstract description 11
- 238000010186 staining Methods 0.000 claims abstract description 8
- 238000004458 analytical method Methods 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 238000000684 flow cytometry Methods 0.000 claims abstract description 5
- 230000004663 cell proliferation Effects 0.000 claims abstract description 4
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 claims description 13
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 238000001262 western blot Methods 0.000 claims description 12
- 230000018109 developmental process Effects 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 239000008055 phosphate buffer solution Substances 0.000 claims description 9
- 238000003753 real-time PCR Methods 0.000 claims description 9
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims description 8
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 230000003698 anagen phase Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 5
- 101100016516 Caenorhabditis elegans hbl-1 gene Proteins 0.000 claims description 5
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 5
- XFAZZQREFHAALG-UHFFFAOYSA-N N-{1-amino-6-[(5-nitro-2-furoyl)amino]-1-oxohexan-2-yl}-23-(indol-3-yl)-20-oxo-4,7,10,13,16-pentaoxa-19-azatricosan-1-amide Chemical compound C=1NC2=CC=CC=C2C=1CCCC(=O)NCCOCCOCCOCCOCCOCCC(=O)NC(C(=O)N)CCCCNC(=O)C1=CC=C([N+]([O-])=O)O1 XFAZZQREFHAALG-UHFFFAOYSA-N 0.000 claims description 5
- 102100023013 Basic leucine zipper transcriptional factor ATF-like 3 Human genes 0.000 claims description 4
- 101000903609 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 3 Proteins 0.000 claims description 4
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims description 4
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims description 4
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 4
- 102000003923 Protein Kinase C Human genes 0.000 claims description 4
- 108090000315 Protein Kinase C Proteins 0.000 claims description 4
- 102000006382 Ribonucleases Human genes 0.000 claims description 3
- 108010083644 Ribonucleases Proteins 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000004043 dyeing Methods 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 claims 16
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 7
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 abstract description 4
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 abstract description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 34
- 108091008875 B cell receptors Proteins 0.000 description 20
- 230000019491 signal transduction Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 108091008819 oncoproteins Proteins 0.000 description 6
- 102000027450 oncoproteins Human genes 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 229940124291 BTK inhibitor Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000001280 germinal center Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003990 molecular pathway Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 101150007337 Bcl6 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101150090105 Ezh2 gene Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000008157 Histone Demethylases Human genes 0.000 description 1
- 108010074870 Histone Demethylases Proteins 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 description 1
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 description 1
- 101150090364 ICP0 gene Proteins 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 101150073900 PTEN gene Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100023876 Rhombotin-2 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 1
- 102100021013 Ubiquitin carboxyl-terminal hydrolase 7 Human genes 0.000 description 1
- 101710167638 Ubiquitin carboxyl-terminal hydrolase 7 Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000033366 cell cycle process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000009504 deubiquitination Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000998 lymphohematopoietic effect Effects 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 108700021653 rel Genes Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of a USP7 inhibitor in a medicine for treating ABC-DLBCL, which is used for researching the expression condition of USP7 in a DLBCL cell line, and then the database analysis shows that the USP7 small-molecule inhibitor is used for inhibiting the activity of USP7, the CCK-8 method is used for observing the influence of cell proliferation, PI staining and flow cytometry on ABC-type DLBCL cell apoptosis and the influence on the ABC-type DLBCL BCR signal path, USP7 is the most widely researched ubiquitin-specific protease at present, the research shows that USP7 participates in regulating the activity and the function of various protein substrates of cells, and USP7 abnormal expression or activity change has important effects on the occurrence and development of diseases and tumors, so that the USP7 inhibitor has good application prospect and market competitiveness, and has good promotion effect on the improvement of China's livelihood and society.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to an application of a USP7 inhibitor in an ABC-DLBCL treatment medicine.
Background
Lymphomas are a group of monoclonal proliferative diseases originating from the lymphohematopoietic system, and are classified into Hodgkin's Lymphoma (HL) and non-Hodgkin's lymphoma (NHL), and about 8.4 million people are diagnosed as lymphomas each year in our country. non-Hodgkin's lymphoma (NHL) is a type of hematological malignancy with significant heterogeneity, divided into B-cell NHL and T/NK-cell NHL by histopathological type. Among the B-NHLs, the most common subtype is diffuse large B-cell lymphoma (DLBCL), with an incidence rate of 45.8% of NHLs. With the widespread use of the rituximab-based immunotherapy regimen (R-CHOP) for the treatment of DLBCL, more than half of patients are cured, but more than 30% of patients still face the risk of relapse, and patients who are not susceptible to R-CHOP chemotherapy will eventually die from DLBCL disease progression, with a 3-year survival rate of less than 60% for high-risk DLBCL cases, to be further improved.
Gene expression profiling and DNA sequencing have deepened our understanding of DLBCL biological properties in the years. DLBCL can be classified into two subtypes, namely, germinal center B-cell-like (GCB) DLBCL and activated B-cell-like (ABC) DLBCL, which have different cell signal activation transduction pathways and different prognosis after standard treatment. The GCB DLBCL is derived from a lymphoid follicle germinal center and expresses CD10, LMO2 and BCL 6. 30% -40% of GCB type DLBCL has t (14, 18), 30% has c-rel gene amplification, 20% can generate histone methyltransferase EZH2 gene mutation, and 10% PTEN gene deletion; EZH2 mediates the generation of GCB-type DLBCL in cooperation with BCL6 gene. The ABC type DLBCL is derived from the plasmablast stage of B cells, and is characterized by the gene pathology that the NF ⁃ kB pathway is continuously activated, so that the tumor cells are actively proliferated and are anti-apoptotic. Most ABC-type DLBCL rely on a chronically activated B-cell receptor (BCR) signaling pathway, which is mediated by B-cell receptors and downstream kinases. These kinases include SYK, PI3K, BTK, and PKC β. Mutations in CD79A/CD79B are present in about 20% of cases; 10% of ABC type DLBCL has CARD11 molecular mutation which can activate NF ⁃ kB pathway independently of upstream signals; deregulation of the negative regulator a20 encoding NF ⁃ kb can occur in 24% of ABC-type DLBCL. In addition, the most critical gene mutation, MYD88, in the TLRs signaling pathway can occur in 30% of ABC-type DLBCLs. However, the specific mechanism of induction of BCR signaling pathway activation remains to be elucidated. From the known data at present, the GCB type DLBCL has low malignancy degree and mainly depends on a PI3K/AKT/MTOR pathway, while the ABC type DLBCL has strong invasiveness and depends on a plurality of growth signal pathways, such as BCR/NF ⁃ kB, JAK-STAT signal pathways and the like. At present, most scholars consider that the prognosis of GCB type DLBCL is obviously better than that of ABC type GCB, and the GCB is an independent prognostic factor.
In recent years, targeted drugs directed to certain molecules in the signaling pathway have been developed in succession or have entered preliminary clinical trials, bringing new promise for the treatment of DLBCL. For example, the inhibitor Ibrutinib of BTK in BCR pathway obtains satisfactory curative effect in ABC type DLBCL which is difficult to cure, and phase I/II clinical research shows that the effective rate can reach 40%. However, because the BTK inhibitor only inhibits BTK molecules downstream of BCR signals, DLBCL especially uses ABC type DLBCL continuously activated by NF ⁃ kB to relate to the expression abnormality of a wide range of signal molecules, the BTK inhibitor only has curative effect on a small part of patients and is easy to generate drug resistance. Given the complexity of the molecular pathway network, a single targeted drug therapy may not be able to exert a long-term and comprehensive anti-tumor effect. Drugs that comprehensively inhibit activation of the BCR signaling pathway remain to be developed.
Ubiquitin-specific protease 7 (USP 7) is currently the most widely studied ubiquitin-specific protease, originally identified from the Herpes Simplex Virus (HSV) protein ICP0 interacting protein and hence also known as herpes virus-associated ubiquitin-specific protease (Hausp). USP7 can specifically hydrolyze ester bond, peptide bond or isopeptide bond formed between the C-terminal of ubiquitin and target protein, so that ubiquitin can be separated from the target protein, thereby affecting the stability, cell location and activity of the target protein. It has the effects of regulating cell cycle process, protein degradation, gene expression, DNA repair and apoptosis. The research finds that the USP7 is involved in the generation and progression of tumors through the interaction with oncoprotein and oncostatin. There are a number of reports in the literature of USP7 on tumorigenesis, which is manifested by its interaction with oncoproteins, deubiquitination to stabilize them, or by inhibition of oncogenic effects of oncoprotein function through interaction with oncoproteins, and a few reports in the literature that USP7 has tumor-inhibiting effects, mainly manifested by its interaction with oncoproteins to stabilize oncoproteins or USP7 to exert gene stability. USP7 is associated with a variety of tumors including lung, colon, breast, glioma, prostate cancer and has received much attention for its role in tumors. However, USP7 has a large difference in substrate and tumor-modulating pathways among different tumors.
Epigenetic regulation is a precise regulatory process involving DNA methylation and histone modification (methylation, acetylation, and phosphorylation). Studies have shown that USP7 can activate DNA methylation by modulating the activity of DNMT 1. USP7 promotes the development and progression of breast cancer by regulating the stabilization of histone demethylase PHF 8. These studies indicate the potential regulatory role of USP7 in histone modification, but the mechanism has not yet been elucidated. There are few reports of studies involving USP7 protein in lymphoma. The research results show that key proteins of USP7 and BCR signal pathway in ABC-DLBCL subtype are highly expressed. Inhibition of USP7 with a small molecule inhibitor of USP7 down-regulates the RNA levels of all key BCR signaling pathway molecules, thereby significantly inducing ABC-DLBCL cell death. The invention not only provides a new visual angle for understanding the pathogenesis of the ABC-DLBCL subtype, but also is expected to provide an effective strategy for the treatment of the ABC-DLBCL subtype.
Diffuse large B-cell lymphoma is the most common non-hodgkin lymphoma, with high incidence, more than 30% of patients are at risk of relapse, and patients insensitive to R-CHOP chemotherapy will eventually die of DLBCL disease progression, for high risk DLBCL cases, 3-year survival rates are still below 60%, to be further improved. Wherein the ABC type DLBCL is more invasive and malignant than other types. The continuous BCR signaling pathway chronic activation is the initiating factor of the ABC type diffuse large B cell lymphoma (ABC-DLBCL) and is also an important therapeutic target of the ABC-DLBCL. In recent years, targeted drugs directed to certain molecules in the signaling pathway have been developed in succession or have entered preliminary clinical trials, bringing new promise for the treatment of DLBCL. For example, the inhibitor Ibrutinib of BTK in BCR pathway obtains satisfactory curative effect in ABC type DLBCL which is difficult to cure, and phase I/II clinical research shows that the effective rate can reach 40%. However, because the BTK inhibitor only inhibits BTK molecules downstream of BCR signals, DLBCL especially uses ABC type DLBCL continuously activated by NF ⁃ kB to relate to the expression abnormality of a wide range of signal molecules, the BTK inhibitor only has curative effect on a small part of patients and is easy to generate drug resistance. Given the complexity of the molecular pathway network, a single targeted drug therapy may not be able to exert a long-term and comprehensive anti-tumor effect. Drugs that comprehensively inhibit activation of the BCR signaling pathway remain to be developed. USP7 is a ubiquitin-specific protease which is the most widely studied at present, and the research shows that USP7 is involved in regulating the activity and the function of various protein substrates of cells, and USP7 has an important role in the occurrence and the development of diseases and tumors due to abnormal expression or activity change. There are few reports of studies involving USP7 protein in lymphoma. Our earlier studies suggest that: compared with the GCB-DLBCL subtype, USP7 is highly expressed in ABC type DLBCL, and the expression difference indicates that the USP7 possibly participates in the generation of ABC-DLBCL. Our study uses USP7 as an entry point, uses USP7 small molecule inhibitors to inhibit USP7 activity, studies the lethality of the inhibitors on ABC type DLBCL cells, and defines the role of USP7 in ABC-DLBCL and determines whether the inhibitors can be used as targets for treating DLBCL.
Disclosure of Invention
The technical problem to be solved is as follows: in view of the above technical problems of risk of relapse and low survival rate, the present invention provides a USP7 inhibitor for use in the treatment of ABC-DLBCL drugs.
The technical scheme is as follows:
use of an inhibitor of USP7 in the treatment of ABC-DLBCL agents.
Further, the method comprises the following steps:
first step, USP7 expresses a relationship with ABC type DLBCL: determining whether USP7 is related to ABC type DLBCL, firstly researching the expression of USP7 in DLBCL cell line, and then analyzing the expression of USP7 in tumor tissue by a database;
secondly, whether USP7 participates in the occurrence and development of ABC type DLBCL and the specific role played by the same is determined: the method is characterized in that a USP7 small molecule inhibitor is used for inhibiting the activity of USP7, the effect of ABC DLBCL cell proliferation, PI staining and apoptosis detection by a CCK-8 method and the effect of the inhibitor on the ABC DLBCL BCR signal channel by Western blot and Real-time PCR detection are observed, and the specific implementation steps are as follows:
and (3) CCK-8 detection: taking cells in logarithmic growth phase, carrying out complete medium resuspension, and counting the cells; taking a sterile 96-well plate, and designing six P22077 concentration groups of 0uM, 0.5uM, 1uM, 5uM, 10uM and 20uM, wherein each concentration group comprises 4 auxiliary wells; inoculating 2 × 104cells to each well, adding complete culture medium containing the above-mentioned concentration of medicine to 200 μ l, continuously culturing for 48h at 37 deg.C under 5% CO2, adding 20 μ l CCK-8 reagent into each well, and incubating for 4 hr at 37 deg.C; taking out the 96-well plate, putting the 96-well plate into an enzyme-labeling instrument, setting the detection wavelength to be 450nm, and detecting and recording OD450 readings;
PI staining experiment: inoculating log-phase cells into a 96-well plate at 20000 cells/well, performing administration treatment, culturing for 24 or 48h, adding PI dye with final concentration of 50 ug/mL, dyeing in dark for 10min, and taking pictures by fluorescence microscope;
flow cytometry: inoculating each group of cells in logarithmic growth phase in a 6-well plate, and culturing for 24 hours; after resuspension, collecting cells in each hole in a single flow tube, centrifuging to remove supernatant, washing the cells for 2 times by PBS (phosphate buffer solution), slowly adding 1ml of 70% ethanol precooled at-20 ℃ into each tube, and standing overnight at 4 ℃; centrifuging to remove ethanol, washing cells with PBS, and centrifuging for 5 min; add 500. mu.l PI/RNase stabilizing Buffer to each tube to resuspend the cells, incubate at room temperature in the dark for 15min, and then check on the machine.
The influence of the inhibitor on the ABC type DLBCL BCR signal channel is detected by applying Real-time PCR and Western blot methods: treating ABC type DLBCL cells (HBL) with 10uM P22077, extracting mRNA and protein respectively, and detecting the mRNA level of target genes IL-6, MYC, BATF3 and IRF4 of BTK, PLCG2, PKC and CD79B and BCR-NFkB signal channels by a Real-time PCR method; the protein levels of BTK and PLCG2 were detected by Western blot method.
Further, the specific step of researching the expression condition of USP7 in the DLBCL cell line in the first step is to apply a Western blot method to detect the expression of USP7 protein in ABC type DLBCL and GCB type DLBCL cell lines, and the expression difference of USP7 in ABC type DLBCL compared with GCB-DLBCL subtype proves that USP7 participates in the generation of ABC-DLBCL.
Further, the database analysis in the first step showed high expression of USP7 in tumor tissues compared to paracarcinoma tissues.
Furthermore, the small molecule inhibitor P22077 of USP7 in the second step can obviously induce the apoptosis of DLBCL, particularly ABC-DLBCL (HBL-1, SU-DHL-2).
Has the advantages that:
1. abnormal expression or activity change of USP7 has important effect on the occurrence and development of diseases and tumors. Database analysis showed high expression of USP7 in tumor tissues compared to paracarcinoma tissues (see figure 1A, B). This difference in expression suggests that our USP7 may be involved in the development of tumors, including DLBCL.
2. Immunoblots showed that USP7 was highly expressed in type ABC DLBCL compared to the GCB-DLBCL subtype (see fig. 1C), suggesting that USP7 may be involved in the development of type ABC DLBCL.
3. Few reports are reported at present about the research of USP7 protein on lymphoma, and the development of corresponding targeted drugs aiming at ABC type DLBCL which is difficult to treat and easy to resist is imminent.
4. The small-molecule inhibitor P22077 USP7 can obviously induce DLBCL, particularly ABC-DLBCL (HBL-1, SU-DHL-2) to undergo apoptosis (see figure 2), and the discovery not only provides a new visual angle for understanding the pathogenesis of ABC-DLBCL subtype, but also is expected to provide an effective strategy for the development of ABC-DLBCL subtype therapeutic drugs.
5. USP7 small molecule inhibitor P22077 can significantly down-regulate ABC type DLBCL cell BCR signaling pathway key molecules (see fig. 3).
6. The method has good application prospect and market competitiveness, and has good promotion effect on improving the livelihood and society of China.
Drawings
FIG. 1 is a graph showing the expression level of USP7 in DLBCL in example 1 of the present application;
FIG. 2 is a graph of the activity of USP7 inhibiting induced apoptosis of DLBCL cells in example 1 of this application.
FIG. 3 is a graph showing that USP7 plays an important role in the up-regulation of key molecules of BCR signaling pathway of ABC-DLBCL cells in example 1 of the present application.
Detailed Description
The following examples illustrate specific steps of the present invention, but are not intended to limit the invention.
Terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art, unless otherwise specified.
The invention is described in further detail below with reference to specific examples and with reference to data. It will be understood that these examples are intended to illustrate the invention and are not intended to limit the scope of the invention in any way.
In the following examples, various procedures and methods not described in detail are conventional methods well known in the art.
Example 1
The use of an inhibitor of USP7 in the treatment of ABC-DLBCL agents, comprising the steps of:
first step, USP7 expresses a relationship with ABC type DLBCL: determining whether USP7 is related to ABC type DLBCL, firstly researching the expression of USP7 in DLBCL cell lines, applying a Western blot method to detect the expression of USP7 protein in ABC type DLBCL and GCB type DLBCL cell lines, and comparing with the GCB-DLBCL subtype, the high expression of USP7 in ABC type DLBCL is higher, the expression difference proves that USP7 participates in the generation of ABC-DLBCL, and then the high expression of USP7 in tumor tissues is shown by database analysis compared with the paracancerous tissues.
As shown in fig. 1, the expression level of USP7 in DLBCL: a, picture A: TCGA database analysis showed that in 31 tumor tissues, USP7 expressed higher in cholangiocarcinoma, thymoma and DLBCL than normal tissues; and B, drawing: USP7 was highly expressed in DLBCL patients compared to the control group; and (C) diagram: compared with GCB-DLBCL subtype (BJAB), the ABC-DLBCL (HBL-1, SU-DHL-2, OCL-Ly 10) subtype has high USP7 expression.
Secondly, whether USP7 participates in the occurrence and development of ABC type DLBCL and the specific role played by the same is determined: USP7 small molecule inhibitor is used for inhibiting activity of USP7, the effect of ABC DLBCL cell proliferation, PI staining and apoptosis detection by a CCK-8 method and the effect of the inhibitor on the ABC DLBCLBCR signal pathway by Western blot and Real-time PCR detection are observed. The specific implementation steps are as follows:
and (3) CCK-8 detection: taking cells in logarithmic growth phase, carrying out complete medium resuspension, and counting the cells; taking a sterile 96-well plate, and designing six P22077 concentration groups of 0uM, 0.5uM, 1uM, 5uM, 10uM and 20uM, wherein each concentration group comprises 4 auxiliary wells; inoculating 2 × 104cells to each well, adding complete culture medium containing the above-mentioned concentration of medicine to 200 μ l, continuously culturing for 48h at 37 deg.C under 5% CO2, adding 20 μ l CCK-8 reagent into each well, and incubating for 4 hr at 37 deg.C; taking out the 96-well plate, putting the 96-well plate into an enzyme-labeling instrument, setting the detection wavelength to be 450nm, and detecting and recording OD450 readings;
PI staining experiment: inoculating log-phase cells into a 96-well plate at 20000 cells/well, performing administration treatment, culturing for 24 or 48h, adding PI dye with final concentration of 50 ug/mL, dyeing in dark for 10min, and taking pictures by fluorescence microscope;
flow cytometry: inoculating each group of cells in logarithmic growth phase in a 6-well plate, and culturing for 24 hours; after resuspension, collecting cells in each hole in a single flow tube, centrifuging to remove supernatant, washing the cells for 2 times by PBS (phosphate buffer solution), slowly adding 1ml of 70% ethanol precooled at-20 ℃ into each tube, and standing overnight at 4 ℃; centrifuging to remove ethanol, washing cells with PBS, and centrifuging for 5 min; add 500. mu.l PI/RNase stabilizing Buffer to each tube to resuspend the cells, incubate at room temperature in the dark for 15min, and then check on the machine.
As shown in figure 2, inhibition of USP7 activity induced apoptosis of DLBCL cells: CCK-8 (panel A), PI staining (panel B) and flow cytometry (panel C) results show that the USP7 small molecule inhibitor P22077 can obviously induce the apoptosis of DLBCL, especially ABC-DLBCL (HBL-1, SU-DHL-2).
The influence of the inhibitor on the ABC type DLBCL BCR signal channel is detected by applying Real-time PCR and Western blot methods: treating ABC type DLBCL cells (HBL) with 10uM P22077, extracting mRNA and protein respectively, and detecting the mRNA level of target genes IL-6, MYC, BATF3 and IRF4 of BTK, PLCG2, PKC and CD79B and BCR-NFkB signal channels by a Real-time PCR method; the protein levels of BTK and PLCG2 were detected by Western blot method.
As shown in FIG. 3, USP7 plays an important role in the upregulation of critical molecules of the BCR signaling pathway in ABC-DLBCL cells. Panel a, mRNA levels of BTK, PLCG2, PKC, and CD79B were significantly down-regulated after P22077 treatment. In panel B, protein levels of BTK and PLCG2 were also significantly down-regulated after P22077 treatment. C picture, after P22077 treatment, the BCR-NFkB signaling pathway target genes IL-6, MYC, BATF3 and IRF4 were significantly down-regulated.
Claims (5)
1. Use of an inhibitor of USP7 in the treatment of ABC-DLBCL agents.
2. The use of an inhibitor of USP7 in the treatment of ABC-DLBCL according to claim 1, characterized by the steps of:
first step, USP7 expresses a relationship with ABC type DLBCL: determining whether USP7 is related to ABC type DLBCL, firstly researching the expression of USP7 in DLBCL cell line, and then analyzing the expression of USP7 in tumor tissue by a database;
secondly, whether USP7 participates in the occurrence and development of ABC type DLBCL and the specific role played by the same is determined: the method is characterized in that a USP7 small molecule inhibitor is used for inhibiting the activity of USP7, the effect of ABC DLBCL cell proliferation, PI staining and apoptosis detection by a CCK-8 method and the effect of the inhibitor on the ABC DLBCL BCR signal channel by Western blot and Real-time PCR detection are observed, and the specific implementation steps are as follows:
and (3) CCK-8 detection: taking cells in logarithmic growth phase, carrying out complete medium resuspension, and counting the cells; taking a sterile 96-well plate, and designing six P22077 concentration groups of 0uM, 0.5uM, 1uM, 5uM, 10uM and 20uM, wherein each concentration group comprises 4 auxiliary wells; inoculation of 2X 10 per well4cells, add complete medium containing the drug at the above concentrations to 200. mu.l, 37 ℃ with 5% CO2Culturing for 48h under the condition, adding 20 μ l CCK-8 reagent into each well, and incubating for 4 hours at 37 ℃; taking out 96-well plate, placing into enzyme labeling instrument, setting detection wavelength at 450nm, detecting and recording OD450 readCounting;
PI staining experiment: inoculating log-phase cells into a 96-well plate at 20000 cells/well, performing administration treatment, culturing for 24 or 48h, adding PI dye with final concentration of 50 ug/mL, dyeing in dark for 10min, and taking pictures by fluorescence microscope;
flow cytometry: inoculating each group of cells in logarithmic growth phase in a 6-well plate, and culturing for 24 hours; after resuspension, collecting cells in each hole in a single flow tube, centrifuging to remove supernatant, washing the cells for 2 times by PBS (phosphate buffer solution), slowly adding 1ml of 70% ethanol precooled at-20 ℃ into each tube, and standing overnight at 4 ℃; centrifuging to remove ethanol, washing cells with PBS, and centrifuging for 5 min; adding 500 μ l PI/RNase stabilizing Buffer into each tube to resuspend cells, incubating at room temperature in dark place for 15min, and detecting on the machine;
the influence of the inhibitor on the ABC type DLBCL BCR signal channel is detected by applying Real-time PCR and Western blot methods: treating ABC type DLBCL cells (HBL) with 10uM P22077, extracting mRNA and protein respectively, and detecting the mRNA level of target genes IL-6, MYC, BATF3 and IRF4 of BTK, PLCG2, PKC and CD79B and BCR-NFkB signal channels by a Real-time PCR method; the protein levels of BTK and PLCG2 were detected by Western blot method.
3. The use of an inhibitor of USP7 in the treatment of ABC-DLBCL agents according to claim 2, wherein: the specific step of researching the expression condition of USP7 in the DLBCL cell line in the first step is to apply a Western blot method to detect the expression of USP7 protein in ABC type DLBCL and GCB type DLBCL cell lines, and the expression difference proves that USP7 participates in the generation of ABC-DLBCL compared with the expression difference of USP7 in ABC type DLBCL of a GCB-DLBCL subtype.
4. The use of an inhibitor of USP7 in the treatment of ABC-DLBCL agents according to claim 2, wherein: database analysis in the first step showed high expression of USP7 in tumor tissues compared to para-carcinoma tissues.
5. The use of an inhibitor of USP7 in the treatment of ABC-DLBCL agents according to claim 2, wherein: the USP7 small-molecule inhibitor P22077 can obviously induce DLBCL, particularly ABC-DLBCL (HBL-1, SU-DHL-2) to generate apoptosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010859627.8A CN111840562A (en) | 2020-08-24 | 2020-08-24 | Application of USP7 inhibitor in ABC-DLBCL treatment drug |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010859627.8A CN111840562A (en) | 2020-08-24 | 2020-08-24 | Application of USP7 inhibitor in ABC-DLBCL treatment drug |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111840562A true CN111840562A (en) | 2020-10-30 |
Family
ID=72967867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010859627.8A Pending CN111840562A (en) | 2020-08-24 | 2020-08-24 | Application of USP7 inhibitor in ABC-DLBCL treatment drug |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111840562A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103492590A (en) * | 2011-02-22 | 2014-01-01 | 卡里斯生命科学卢森堡控股有限责任公司 | Circulating biomarkers |
CN108823640A (en) * | 2018-06-06 | 2018-11-16 | 珠海铂华生物工程有限公司 | A kind of method and its application constructing the high-throughput sequencing library based on lymthoma genetic test |
-
2020
- 2020-08-24 CN CN202010859627.8A patent/CN111840562A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103492590A (en) * | 2011-02-22 | 2014-01-01 | 卡里斯生命科学卢森堡控股有限责任公司 | Circulating biomarkers |
CN108823640A (en) * | 2018-06-06 | 2018-11-16 | 珠海铂华生物工程有限公司 | A kind of method and its application constructing the high-throughput sequencing library based on lymthoma genetic test |
Non-Patent Citations (3)
Title |
---|
HEE等: "Genome-Scale ORF Screen for Mediators of NF-κb Activation in DLBCL", 《BLOOD》 * |
张超等: "去泛素化酶- USP7通过影响相关癌蛋白参与肿瘤的发生与发展", 《现代肿瘤医学》 * |
游琴: "去泛素化酶USP7在急性T淋巴细胞白血病中的功能研究", 《中国优秀硕士学位论文全文数据库》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhai et al. | A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma | |
Toffanin et al. | MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a | |
Wang et al. | Human tumor microRNA signatures derived from large‐scale oligonucleotide microarray datasets | |
Zhang et al. | Upregulation of FEN1 is associated with the tumor progression and prognosis of hepatocellular carcinoma | |
Hsieh et al. | H3K27me3 loss plays a vital role in CEMIP mediated carcinogenesis and progression of breast cancer with poor prognosis | |
Song et al. | ATF-3/miR-590/GOLPH3 signaling pathway regulates proliferation of breast cancer | |
Wang et al. | Gene expression profiling reveals distinct molecular subtypes of esophageal squamous cell carcinoma in Asian populations | |
Xu et al. | Epigenetic induction of tumor stemness via the lipopolysaccharide-TET3-HOXB2 signaling axis in esophageal squamous cell carcinoma | |
Chen et al. | Targeted methylation of the LncRNA NEAT1 suppresses malignancy of renal cell carcinoma | |
Karlsson et al. | Aberrant epigenetic regulation in clear cell sarcoma of the kidney featuring distinct DNA hypermethylation and EZH2 overexpression | |
Kim et al. | EphA3 maintains radioresistance in head and neck cancers through epithelial mesenchymal transition | |
Lin et al. | MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer | |
Pan et al. | Ectopic expression of microRNA-874 represses epithelial mesenchymal transition through the NF-κB pathway via CCNE1 in cholangiocarcinoma | |
Sun et al. | NOP2-mediated m 5 C methylation of XPD is associated with hepatocellular carcinoma progression. | |
Ma et al. | ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma | |
Wei et al. | Prognostic value and immunological role of FOXM1 in human solid tumors | |
CN111840562A (en) | Application of USP7 inhibitor in ABC-DLBCL treatment drug | |
Liu et al. | Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas | |
Chen et al. | Integrated Bioinformatic analysis identifies TIPIN as a prognostic biomarker in hepatocellular carcinoma | |
CN112114143B (en) | Application of hepatoma diagnosis and cancer-causing kinase treatment marker | |
Fan et al. | The immune regulation of BCL3 in glioblastoma with mutated IDH1 | |
Fang et al. | Hsa_circ_0003596 enhances the development of cell renal clear cell carcinoma through the miR‐502‐5p/IGF1/PI3K/AKT axis | |
Huang et al. | Integrated single-cell and transcriptome sequencing analyses develop a ubiquitination-associated signature in gastric cancer and identified OTULIN as a novel biomarker | |
Jin et al. | USP20 is a predictor of poor prognosis in colorectal cancer and associated with lymph node metastasis, immune infiltration and chemotherapy resistance | |
CN112501291A (en) | Application of NAMPT in preparation of kit for predicting sensitivity of solid tumor patient to immune checkpoint inhibitor therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |